• Medientyp: E-Book; Hochschulschrift
  • Titel: Nafisamycin, cyclisation product of a new enediyne precursor, highly cytotoxic mansouramycins, karamomycins possessing a novel heterocyclic skeleton and further unusual secondary metabolites from terrestrial and marine bacteria
  • Paralleltitel: Nafisamycin, das Cyclisierungsprodukt einer neuen Endiin-Vorstufe, cytotoxische Mansouramycine, Karamomycine mit einem neuen heterocyclischen Grundgerüst und weitere ungewöhnliche Sekundärstoffe aus terrestrischen und marinen Bakterien
  • Beteiligte: Mahmoud, Khaled Attia Shaaban [VerfasserIn]
  • Erschienen: 2008
    [2009]
  • Umfang: Online-Ressource (PDF-Datei: 411 S., 4.920 KB); Ill., graph. Darst
  • Sprache: Englisch
  • Identifikator:
  • Schlagwörter: Hochschulschrift
  • Reproduktionsnotiz: Online-Ausg
  • Entstehung:
  • Hochschulschrift: Göttingen, Univ., Diss., 2009
  • Anmerkungen:
  • Beschreibung: The search for new medically active compounds to overcome the countless diseases is one of the most relevant objectives worldwide. Medicinal plants were used previously in the traditional medicine and even now are important for the treatment of certain infections. However, the appearance of new diseases and new drug resistances stimulated the search for new sources of bioactive agents. The marine environment comprises nearly three quarters of the earth’s surface, and can be considered as a soup of all imaginable types of microbes. Marine microorganisms, particularly bacteria, have provided new incentives for investigating marine natural products over the past 15 years, and also continue to be the subject of vigorous chemical investigation. This highlights their importance as a source of natural products. So, the search for new biologically active natural metabolites in bacteria may enable us to cure such drug resistances and unusual infectious diseases. In the present study, 10 terrestrial Streptomycetes and 15 marine-derived bacterial strains were selected on the bases of a chemical and biological screening ...
  • Zugangsstatus: Freier Zugang